Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

To date, 14 patients have now been enrolled in the expanded access program. The first 10 patients have all shown either an improvement or stability of disease within 6 months ...

Seventy-eight-year-old Joe Walsh, of Quincy, is in a unique position. He is the first patient to have permission from the U.S. Food and Drug Administration to try a nasal spray for moderate ...

Senate committee members heard arguments on a bill that would place a 10-year pause on administering mRNA vaccines in Idaho ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Coronary artery lesions in patients with SARS-CoV-2 infection more likely to become high-risk plaques. HealthDay News — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

As recent research links the Mediterranean diet to reducing long COVID-19 risks, the Mayo Clinic releases a Superfoods Meal ...